Common use of NOTIFICATIONS AND SUBMISSION OF REPORTS Clause in Contracts

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx Xxxxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 AstraZeneca: Xxxxx X. Xxxxxxx U.S. Compliance Officer AstraZeneca Pharmaceuticals LP 0000 Xxxxxxx Xxxx XX Xxx 00000 Xxxxxxxxxx, XX 00000-0000 Telephone: 000.000.0000 Facsimile: 302.885.9093 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK AstraZeneca may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Extendicare: Xxxxx Xxxxx Vice President and Chief Compliance Officer 000 X. Xxxxxxxx Xxxxxx Xxxxxxxxx, XX 00000 Telephone: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Extendicare may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. ‌‌ Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: OIG:‌ Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Prime:‌ Xxxx Vice President & Xxxxxxxxx Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 Prime Healthcare 0000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxx Xxxxxxx, XX 00000 Telephone: 000.000.0000 FacsimileEmail: 215.751.7547 XXxxxxxxxx@xxxxxxxxxxxxxxx.xxx Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Prime may be required to provide OIG with an electronic additional copy of each notification or report required by this CIA CIA, in searchable portable document OIG’s requested format (pdfelectronic or paper), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 CEPHALON: Executive Vice President, Chief Compliance Officer Cephalon, Inc. 00 Xxxxxx Xxxx Frazer, PA 19355 Phone: (000) 000-0000 Facsimile: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Cephalon may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Boston Scientific: Xxxx Xxxxxxxx Xxxxx Chief Compliance Officer Xxx Xxxxxx Xxxxx Xxxxx Xxxxx, XX 00000 Telephone No: 000-000-0000 Facsimile No: 000-000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Boston Scientific may be required to provide OIG with an electronic copy of each Boston Scientific Corp. Corporate Integrity Agreement notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKRadeas: Xxxxx Xxxxxx Compliance Specialist 000 Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Xxxxxxx Xxxxxx Xxxxx 000 X. 00xx Xxxxxx Xxxxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 919.516.0096 Email Address: xxxxx.xxxxxx@xxxxxx.xxx Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Radeas may be required to provide OIG with an electronic additional copy of each notification or report required by this CIA CIA, in searchable portable document OIG’s requested format (pdfelectronic or paper), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKGGNSC: Xxxxx X. Xxxxxxx X. Xxxx Vice President & Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Golden Living 0000 Xxxxx Xxxxxx Xxxxxxx Xxxxx 000 X. 00xx Xxxxxx XxxxxxxxxxxxPlano, XX 00000 TX 75024 Telephone: 000.000.0000 000-000-0000 Facsimile: 215.751.7547 000-000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK GGNSC may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. ‌ Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: OIG:‌ Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General General‌ U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Northwell Health, Inc. and Lenox Hill Hospital:‌ Senior Vice President and General Counsel 0000 Xxxxxx Xxxxxx Xxx Xxxx Xxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 516.465.6360 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Northwell may be required to provide OIG with an electronic additional copy of each notification or report required by this CIA CIA, in searchable portable document OIG’s requested format (pdfelectronic or paper), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKBIPI: Xxxxxxx X. Xxxx Vice President & Xxxxxxxxxx Xxxxxxxxx Chief Ethics and Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxx Xxxx Ridgefield, XX 00000 CT 00000-0000 Telephone: 000.000.0000 Facsimile: 215.751.7547 203.791.6260 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK BIPI may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. ‌ Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: OIG:‌ Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General General‌‌‌ U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Spring Gate:‌ Xxxxx Xxxxxxxx, Compliance Officer 0000 Xxx XxXxxxxx Xxxx, Xxxxx 000 Xxxxxxxxxx, XX 00000 Office: 000-000-0000 Fax: 000-000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Spring Gate may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Elan: Xxxxxxx Xxxxxxx-Xxxxx Senior Vice President and Chief Compliance Officer 000 Xxxxxxx Xxxxxxxxx Xxxxx Xxx Xxxxxxxxx, XX 00000 Telephone: 000.000.0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Elan may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 202.205.0604 GSK(000) 000-0000 ION: Xxxxxxx Xxxxx XxXxxxxx, Compliance Director Integrated Oncology Network 0000 X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Xxxxx Xxxxxxx, Xxxxx 000 X. 00xx Xxxxxx Xxxxxxxxxxxxxxx Xxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK ION may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf)CIA, either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Rotech: Xxxxx Xxxxxxx Chief Compliance Officer Rotech Healthcare Inc. 0000 Xxxxxxxxxx Xxxxx Xxxxx 000 Xxxxxxx, XX 00000 Phone: 000-000-0000 Fax: 000-000-0000 Rotech Healthcare Inc. Corporate Integrity Agreement Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Rotech may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXX Xxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 La Fuente 000 XX 0xx Xxxxxx Xxxxxxxx Xxxx, XX 00000 Telephone: (000) 000-0000 Facsimile: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK La Fuente may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKDaiichi: Xxxxxxx X. Xxxx Xxxxxxxxxx Vice President Ethics & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxxx Xxxxxx, Inc. 0 Xxxxxx XxxxxxxxxxxxXxxxx Parsippany, XX 00000 NJ 07054 Telephone: 000.000.0000 Facsimile: 215.751.7547 973.205.2808 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Daiichi may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Cxxxx Building, Room 5527 000 300 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 200.000.0000 Facsimile: 215.751.7547 202.205.0604 Baxano Surgical: Sxxxxxxxx Xxxxx Vice President of Regulatory, Quality and Compliance and Chief Compliance Officer 100 Xxxxxxx Xxxxx Xxxxxxx, XX 00000 Telephone: 900-000-0000 Facsimile: 900-000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Baxano Surgical may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKMid Xxxxxx: Xxxxxxx X. Xxxx Vice President & Xxxxxxxxx Xxxx, Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza & Chief Operating Officer 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxx Xxxxx Fishkill, XX 00000 NY 12524 Telephone: 000.000.0000 Facsimile: 215.751.7547 845.231.5492 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Mid Xxxxxx may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Orthofix: Xxxx X. Xxxxx Orthofix International, N.V. Senior Vice President & Chief Compliance Officer 0000 Xxxxx Xxxxxxx Xxxxxxxxxx, XX 00000 Office: 214.937.2776 Facsimile: 214.937.3014 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Orthofix may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. WashingtonXxxxxxxxxx, DC 20201 XX 00000 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKLilly: Xxxxxxx X. Xxxx Vice President & Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx Xxx Xxxxx and Company Lilly Corporate Center, DC 1114 Xxxxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 317.655.1921 Corporate Integrity Agreement Xxx Xxxxx Company 38 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Lilly may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General General‌ U.S. Department of Health and Human Services Endo Pharmaceuticals Inc. Corporate Integrity Agreement Xxxxx Building, Room 5527 0000 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKEndo: Xxx Xxxxxxx X. Xxxx Executive Vice President & and Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxEndo Health Solutions Inc. 0000 Xxxxxxx Xxxxx Malvern, XX 00000 PA 19335 Telephone: 000.000.0000 Facsimile: 215.751.7547 484.713.5204 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK EPI may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Maxim: Xxxxxxxxxx X. Xxxxxxxx Vice President & Chief Compliance Officer Maxim Healthcare Services, Inc. 0000 Xxx Xxxxxxxx Drive Columbia, MD 21046 Telephone: 000.000.0000 Facsimile: 410.872.9417 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Maxim may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf.pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKOCOM: Xxxxxxx X. Xxxx Vice President & Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx United Surgical Partners International 00000 Xxxxxx XxxxxxxxxxxxXxxxxxx, XX 00000 Addison, TX 75254 Telephone: 000.000.0000 Facsimile000-000-0000 Email: 215.751.7547 XXXX_Xxxxxxxxxx@xxxx.xxx Unless otherwise specified, all notifications and reports required by this CIA may shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK OCOM may be required to provide OIG with an electronic additional copy of each notification or report required by this CIA CIA, in searchable portable document OIG’s requested format (pdfelectronic or paper), either instead of or in addition to, a paper copy.